Pfizer Japan Inc has received manufacturing and marketing authorisation for Champix tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for smokers dependent on nicotine.
Champix is Japan's first oral smoking cessation aid developed for smoking cessation treatment. Current 'Nicotine Replacement Therapy' relieves withdrawal symptoms associated with smoking cessation by replacing tobacco with nicotine. Champix brings about a smoking cessation effect as a non-nicotine partial agonist that binds to a42 nicotine receptors in the brain with strong affinity.
Champix relieves withdrawal symptoms and tobacco craving associated with smoking cessation by acting as an agonist for a42 nicotine receptors in the brain, which are associated with nicotine dependence.
Read More
No comments:
Post a Comment